NO20033684L - Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater - Google Patents

Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater

Info

Publication number
NO20033684L
NO20033684L NO20033684A NO20033684A NO20033684L NO 20033684 L NO20033684 L NO 20033684L NO 20033684 A NO20033684 A NO 20033684A NO 20033684 A NO20033684 A NO 20033684A NO 20033684 L NO20033684 L NO 20033684L
Authority
NO
Norway
Prior art keywords
treatment
epothilone derivatives
refractory tumors
tumors
refractory
Prior art date
Application number
NO20033684A
Other languages
English (en)
Other versions
NO20033684D0 (no
Inventor
Francis Y F Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23028846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033684(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033684D0 publication Critical patent/NO20033684D0/no
Publication of NO20033684L publication Critical patent/NO20033684L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
NO20033684A 2001-02-20 2003-08-19 Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater NO20033684L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26983601P 2001-02-20 2001-02-20
PCT/US2002/004255 WO2002066038A1 (en) 2001-02-20 2002-02-06 Treatment of refractory tumors using epothilone derivatives

Publications (2)

Publication Number Publication Date
NO20033684D0 NO20033684D0 (no) 2003-08-19
NO20033684L true NO20033684L (no) 2003-10-13

Family

ID=23028846

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033684A NO20033684L (no) 2001-02-20 2003-08-19 Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater

Country Status (18)

Country Link
US (2) US6686380B2 (no)
EP (1) EP1385529A4 (no)
JP (1) JP2004522774A (no)
KR (1) KR20040025895A (no)
CN (1) CN1774253A (no)
BG (1) BG108075A (no)
BR (1) BR0207487A (no)
CA (1) CA2438610A1 (no)
EE (1) EE200300396A (no)
HU (1) HUP0303175A2 (no)
IL (1) IL156988A0 (no)
IS (1) IS6918A (no)
MX (1) MXPA03007394A (no)
NO (1) NO20033684L (no)
PL (1) PL363362A1 (no)
RU (1) RU2003128311A (no)
WO (1) WO2002066038A1 (no)
ZA (1) ZA200306173B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
EP1353667A1 (en) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4791183B2 (ja) * 2002-08-23 2011-10-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロン、その中間体、類似体の合成およびその使用
JP2006504743A (ja) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
WO2006017761A2 (en) * 2004-08-05 2006-02-16 Emory University Epothilone analogues as therapeutic agents
CA2588400A1 (en) 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising ixabepilone, and preparation thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
CN101535492A (zh) 2005-02-11 2009-09-16 南加州大学 表达含有二硫键的蛋白质的方法
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
BR112022013685A2 (pt) 2020-01-10 2022-09-06 R Pharm Us Operating Llc Composições de ixabepilona

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2198752A1 (en) * 1994-08-31 1996-03-07 Jason Scott Sawyer Methods for identifying and treating resistant tumors
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
WO1997019086A1 (de) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilonderivate, herstellung und verwendung
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
EP1367057B1 (de) 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone E und F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
JP2000510425A (ja) 1997-03-06 2000-08-15 ハリー・ニジェンフイス・マネージメント・ビー・ヴイ コンテナおよびコンテナ台車を移送するターミナル
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
ATE225783T1 (de) 1997-04-18 2002-10-15 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ATE224882T1 (de) 1997-07-16 2002-10-15 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
AU9340998A (en) 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6982142B2 (en) * 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
ES2324378T3 (es) 1998-02-05 2009-08-05 Novartis Ag Composicion farmaceutica que contiene epotilona.
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
ATE248175T1 (de) 1998-12-22 2003-09-15 Novartis Pharma Gmbh Epothilonderivate und ihre verwendung als antitumormittel
IL144519A0 (en) 1999-02-18 2002-05-23 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
AU771089B2 (en) 1999-02-22 2004-03-11 Bristol-Myers Squibb Company C-21 modified epothilones
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
FR2793288B1 (fr) 1999-05-06 2001-07-20 Transrol Rotule permettant la transmission d'un couple
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
ATE389401T1 (de) 2001-01-25 2008-04-15 Bristol Myers Squibb Co Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
RS20050235A (en) 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
US7460891B2 (en) 2002-10-21 2008-12-02 Microsoft Corporation Method and system to shut down and control computer radios

Also Published As

Publication number Publication date
IL156988A0 (en) 2004-02-08
HUP0303175A2 (hu) 2003-12-29
CN1774253A (zh) 2006-05-17
WO2002066038A1 (en) 2002-08-29
IS6918A (is) 2003-08-18
EE200300396A (et) 2003-12-15
NO20033684D0 (no) 2003-08-19
BR0207487A (pt) 2004-08-10
ZA200306173B (en) 2004-11-23
US6686380B2 (en) 2004-02-03
USRE41393E1 (en) 2010-06-22
MXPA03007394A (es) 2003-12-04
BG108075A (bg) 2005-04-30
KR20040025895A (ko) 2004-03-26
EP1385529A4 (en) 2007-05-09
PL363362A1 (en) 2004-11-15
EP1385529A1 (en) 2004-02-04
RU2003128311A (ru) 2005-03-10
US20020165258A1 (en) 2002-11-07
CA2438610A1 (en) 2002-08-29
JP2004522774A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
NO20033684L (no) Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater
NO20033682D0 (no) Epothilone-derivater for behandling av refraktor-tumorer
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
NO20035522D0 (no) Kinuklidin-substituerte multisykliske heteroaryler for behandling av sykdom
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
NO20041368D0 (no) Azabicyklus-substituerte kondenserte heteroarylforbindelser for behandling av sykdom
NO20034523L (no) Pyrazolderivater for behandling av HIV
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20026008D0 (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
DE60223841D1 (de) Medizinische verwendung von gsk3-hemmenden oxindolderivaten
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
NO20033883L (no) Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20040087L (no) Fremgangsmate for behandling av sovnloshet
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
NO20043113L (no) Fremgangsmate for behandling av benforstyrrelse
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
NO20033290D0 (no) Pyrrolderivater for behandling av cytokinformidlede sykdommer
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application